Trial record 6 of 326 for:
Open Studies | "Hepatitis C"
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Weill Medical College of Cornell University.
Recruitment status was Recruiting
Vertex Pharmaceuticals Incorporated
Information provided by:
Weill Medical College of Cornell University
First received: April 30, 2009
Last updated: August 27, 2010
Last verified: August 2010
The purpose of this study is to determine the decline of virus in the blood and liver in patients treated with telaprevir, pegylated interferon and ribavirin.
Fine Needle Aspiration (FNA) procedure will be used to repeatedly sample the liver to enhance the understanding of how the virus decays in the liver in response to treatment with anti-viral compounds and the measurement of the concentration of the drugs in the liver. FNA is an alternative procedure to core needle biopsy in its ability to repeatedly sample the liver with significantly reduced morbidity.
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||#0810010040: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus Infection: A Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C
Primary Outcome Measures:
- Intrahepatic and plasma HCV viral kinetics in subjects treated with telaprevir, pegylated interferon and ribavirin [ Time Frame: Day-7, Day 1, Day 4, Day 15, Week 12, Week 16, Week 48 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Intrahepatic and peripheral pharmacokinetic assessment of telaprevir [ Time Frame: Day-7, Day 1, Day 4, Day 15, Week 12, Week 16, Week 48 ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2012 (Final data collection date for primary outcome measure)
15 subjects will receive Telaprevir in combination with pegylated interferon and ribavirin and 5 additional subjects on standard of care.
Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg). Additional 5 subjects be on standard of therapy.
|Ages Eligible for Study:
||18 Years to 65 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male and female subjects, 18-65 years of age, inclusive.
- Cases will be genotype 1 (confirmed by standard testing). Enrollment of controls will not be restricted by genotype.
All patients must show evidence of chronic hepatitis C, confirmed by detectable plasma HCV RNA. Chronic disease status must be confirmed by at least one of the following standard criteria:
History of a remote risk factor, or Abnormal ALT levels for >6 months prior to screening period (Note: elevated ALT is not an inclusion criteria, if one of the other criteria for "chronic" hepatitis C is met), or Detectable HCV RNA for at least 6 months before the screening period
- Liver biopsy obtained within 24 months of study enrollment demonstrating absence of cirrhosis (stage 0-3) for cases. Enrollment of controls will not be restricted by stage of fibrosis.
- Judged to be in good health on the basis of medical history and physical examination (including vital signs and ECG), with any chronic medical conditions under stable medical control.
Screening Visit laboratory values must be within the following:
- Laboratory variable: acceptable range
- Absolute neutrophil count: 1200/cmm³
- Platelet count: 90,000/cmm³
- Hemoglobin: within normal range
- HbsAg (screening visit only): seronegative
- HIV1 and 2 Ab (screening visit only): seronegative
In addition, all other hematology and clinical chemistry must be within normal limits or show no clinically significant abnormalities.
- Subjects (or their female partners) must be not pregnant, planning to become pregnant within the next 72 weeks, or they must be permanently sterile or otherwise of non childbearing potential. They must also not be breastfeeding. If of child-bearing potential, subjects must agree to use 2 effective methods of contraception from screening through 6 months after the last dose of RBV. Male subjects who have a female partner of childbearing potential must agree to use 2 effective methods of contraception from Screening through 7 months after the last dose of RBV unless vasectomized.
- Female subjects must have a negative pregnancy test at all visits (screening and predose Day 1) before the first dose of study drugs.
- Willing to refrain from the concomitant use of any medications, substances or foods.
- Able to read and understand the Informed Consent Form (ICF) and willing to sign the ICF and abide by the study requirements and restrictions.
- Received more than 4 weeks of any approved or investigational drug or drug regimen for the treatment of hepatitis C.
Any medical contraindications to Peg-IFN alpa-2a or RBV therapy, including any of the following:
- Abnormal thyroid stimulating hormone (TSH) levels or poorly controlled thyroid function
- Evidence of clinically significant cardiac dysfunction;
- History of psychiatric disorders determined by the investigator to contraindicate the use of IFN-based therapy;
- Antinuclear antibody (ANA) titer 1:320;
- History of hemoglobinopathies.
- Patients coinfected with either human immunodeficiency virus (HIV) or hepatitis B virus (HBV).
- Decompensated liver disease as indicated by a history of ascites, hepatic encephalopathy, or bleeding esophageal varices.
- Diagnosed or suspected hepatocellular carcinoma. Alfa-fetoprotein (AFP) during screening must be less than 100 ng/mL.
For cases, histologic evidence of hepatic cirrhosis on any liver biopsy
o Most recent liver biopsy must be within 2 years prior to study screening.
- Has taken any of the prohibited medications within 28 days of initiation of therapy.
- A history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include but is not limited to a history of relevant drug or food allergies, history of cardiovascular or central nervous system disease, history or presence of clinically significant illness, or history of mental illness that may affect compliance with study requirements.
- Alcohol abuse or excessive use (in the opinion of the investigator, as judged by medical history) in the last 12 months.
- Participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).
- For cases, hypersensitivity to tartrazine (known as yellow dye #5).
- Men whose female partners are pregnant
Please refer to this study by its ClinicalTrials.gov identifier: NCT00892697
|Weill Cornell Medical College
|New York, New York, United States, 10065 |
|Contact: Andrew H. Talal, MD, MPH 212-746-9445 |
|Principal Investigator: Andrew H. Talal, MD, MPH |
Weill Medical College of Cornell University
Vertex Pharmaceuticals Incorporated
||Andrew H. Talal, MD, MPH
||Weill Medical College of Cornell University
No publications provided
||Andrew H. Talal, MD, MPH, Weill Medical College of Cornell University,
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 30, 2009
||August 27, 2010
||United States: Institutional Review Board
United States: Food and Drug Administration
Keywords provided by Weill Medical College of Cornell University:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 12, 2013
Digestive System Diseases
Hepatitis, Viral, Human
RNA Virus Infections